Stuart C. Gordon, Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B. Martins, Leland J. Yee, John F. Flaherty, Kathryn M. Kitrinos, Vinod K. Rustgi, Patrick Marcellin – 30 January 2013 – We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment.

Jason D. Coombes, Wing‐Kin Syn – 29 January 2013

Vincenzo Cardinale, Guido Carpino, Lola M. Reid, Eugenio Gaudio, Domenico Alvaro – 29 January 2013

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Dale J. Hu, Jian Xing, Rania A. Tohme, Youlian Liao, Henry Pollack, John W. Ward, Scott D. Holmberg – 28 January 2013 – Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009‐2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S.

Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.

Jaime Bosch – 28 January 2013

Richard J. Aspinall – 28 January 2013

Paul J. Pockros, Donald Jensen, Naoky Tsai, Ryan Taylor, Alnoor Ramji, Curtis Cooper, Rolland Dickson, Alan Tice, Rohit Kulkarni, John M. Vierling, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the JUMP‐C Investigators – 28 January 2013 – Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA‐dependent RNA polymerase, with activity across all HCV genotypes.

Zi Yin, Chao Liu, Yajin Chen, Yu Bai, Changzhen Shang, Rongyan Yin, Dong Yin, Jie Wang – 28 January 2013 – The optimal surgical strategy for treatment of patients with synchronous colorectal liver metastases (SCLRM) remains controversial. We conducted a systematic review and meta‐analysis of all observational studies to define the safety and efficacy of simultaneous versus delayed resection of the colon and liver. A search for all major databases and relevant journals from inception to April 2012 without restriction on languages or regions was performed.